Yann Wallez
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, HER2/EGFR in Cancer Research, DNA Repair Mechanisms, Cancer Genomics and Diagnostics, Cancer therapeutics and mechanisms
Most-Cited Works
- → Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis(2007)466 cited
- → Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site(2006)227 cited
- → Vascular Endothelial–Cadherin Tyrosine Phosphorylation in Angiogenic and Quiescent Adult Tissues(2005)129 cited
- → Angiogenesis: The VE-Cadherin Switch(2006)127 cited
- → Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK(2013)109 cited
- → The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression(2018)107 cited
- → Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models(2020)58 cited
- → Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305(2022)56 cited
- → Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine(2018)42 cited
- → Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity(2015)42 cited